With thought it was easy to see that in GTP's case a restoration of the tax incentive and legitimisation by the ATO and Federal Government of Bluegum Investment deductabilities would make GTP (and its stable mates) favoured investment products for those seeking tax relief. And just as death is certain - so is the desire to minimise tax for those with large taxable incomes. And as with the banks, the best investment is not always in the institutions products but in the institution itself.
GTP simply had their ship come in first.
CST has a similar foreseeable future in that the product was obviously one with a huge market but it lacked 'legitimicy' (if we can call it that) until the FDA granted approval.
That is now done and in my mind the sky is the limit as long as CST do all the right 'business' things.
Everything to date suggests to me they have and will.
Congratulations on your early call and investments.
Not many biotechs (especially Australian biotechs) ever get their good ideas to fruition (even less under their own control).
You picked it.
Cheers,
CST Price at posting:
0.0¢ Sentiment: None Disclosure: Not Held
